T. Rowe Price Associates
GSK icon

T. Rowe Price Associates’s GSK GSK Stock Holding History

T. Rowe Price Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404M Sell
7,322,833
-571,896
-7% -$31M 0.05% 290
2025
Q4 		$387M Sell
7,894,729
-57,283
-0.7% -$2.67M 0.04% 304
2025
Q3 		$343M Sell
7,952,012
-94,380
-1% -$3.69M 0.04% 334
2025
Q2 		$309M Buy
8,046,392
+324,078
+4% +$12.4M 0.04% 344
2025
Q1 		$299M Buy
7,722,314
+155,392
+2% +$5.69M 0.04% 344
2024
Q4 		$256M Buy
7,566,922
+35,134
+0.5% +$1.26M 0.03% 377
2024
Q3 		$308M Sell
7,531,788
-2,700,488
-26% -$110M 0.04% 359
2024
Q2 		$394M Sell
10,232,276
-1,233,137
-11% -$51.9M 0.05% 309
2024
Q1 		$492M Sell
11,465,413
-1,353,545
-11% -$55.8M 0.06% 276
2023
Q4 		$475M Buy
12,818,958
+52,133
+0.4% +$1.87M 0.06% 266
2023
Q3 		$463M Sell
12,766,825
-265,296
-2% -$9.42M 0.07% 245
2023
Q2 		$464M Buy
13,032,121
+739,208
+6% +$26.5M 0.06% 260
2023
Q1 		$437M Buy
12,292,913
+673,419
+6% +$23.6M 0.07% 259
2022
Q4 		$408M Buy
11,619,494
+434,976
+4% +$14.5M 0.07% 263
2022
Q3 		$331M Sell
11,184,518
-690,456
-6% -$26.2M 0.05% 281
2022
Q2 		$646M Sell
11,874,974
-274,928
-2% -$15.2M 0.08% 238
2022
Q1 		$662M Buy
12,149,902
+53,743
+0.4% +$2.92M 0.07% 281
2021
Q4 		$667M Buy
12,096,159
+273,665
+2% +$14.2M 0.06% 299
2021
Q3 		$565M Buy
11,822,494
+87,602
+0.7% +$4.4M 0.05% 327
2021
Q2 		$584M Sell
11,734,892
-699,733
-6% -$33.6M 0.05% 313
2021
Q1 		$555M Sell
12,434,625
-807,069
-6% -$36.6M 0.06% 311
2020
Q4 		$609M Sell
13,241,694
-908,912
-6% -$41.8M 0.06% 294
2020
Q3 		$666M Buy
14,150,606
+51,860
+0.4% +$2.6M 0.08% 261
2020
Q2 		$719M Buy
14,098,746
+366,244
+3% +$18.8M 0.09% 231
2020
Q1 		$650M Buy
13,732,502
+1,532,935
+13% +$81.8M 0.1% 210
2019
Q4 		$717M Buy
12,199,567
+4,532
+0% +$252K 0.09% 236
2019
Q3 		$651M Buy
12,195,035
+71,315
+0.6% +$3.67M 0.09% 231
2019
Q2 		$606M Sell
12,123,720
-1,363,511
-10% -$68.4M 0.09% 245
2019
Q1 		$705M Sell
13,487,231
-985,646
-7% -$49.3M 0.1% 207
2018
Q4 		$691M Buy
14,472,877
+1,386,596
+11% +$68.3M 0.12% 183
2018
Q3 		$657M Sell
13,086,281
-255,185
-2% -$13M 0.1% 219
2018
Q2 		$672M Buy
13,341,466
+172,419
+1% +$8.68M 0.1% 206
2018
Q1 		$643M Sell
13,169,047
-87,235
-0.7% -$4.06M 0.1% 209
2017
Q4 		$588M Sell
13,256,282
-110,328
-0.8% -$5.1M 0.1% 227
2017
Q3 		$678M Buy
13,366,610
+2,605,897
+24% +$132M 0.12% 187
2017
Q2 		$580M Buy
10,760,713
+2,217,867
+26% +$118M 0.1% 215
2017
Q1 		$450M Buy
8,542,846
+228,571
+3% +$11.6M 0.08% 255
2016
Q4 		$400M Buy
8,314,275
+1,844,253
+29% +$91.1M 0.08% 274
2016
Q3 		$349M Buy
6,470,022
+265,484
+4% +$14.6M 0.07% 283
2016
Q2 		$336M Buy
6,204,538
+648,646
+12% +$34.2M 0.07% 292
2016
Q1 		$282M Sell
5,555,892
-1,043,875
-16% -$52M 0.06% 323
2015
Q4 		$333M Buy
6,599,767
+147,339
+2% +$7.51M 0.07% 290
2015
Q3 		$310M Buy
6,452,428
+1,471,730
+30% +$76.6M 0.07% 303
2015
Q2 		$259M Sell
4,980,698
-2,047,108
-29% -$115M 0.05% 379
2015
Q1 		$405M Buy
7,027,806
+325,276
+5% +$18.6M 0.08% 276
2014
Q4 		$358M Buy
6,702,530
+40,376
+0.6% +$2.26M 0.08% 302
2014
Q3 		$383M Sell
6,662,154
-569,711
-8% -$34.9M 0.08% 275
2014
Q2 		$483M Buy
7,231,865
+33,683
+0.5% +$2.28M 0.1% 230
2014
Q1 		$481M Buy
7,198,182
+592,587
+9% +$40.1M 0.11% 231
2013
Q4 		$441M Buy
6,605,595
+1,057,746
+19% +$68.6M 0.1% 243
2013
Q3 		$348M Sell
5,547,849
-457,972
-8% -$29.5M 0.09% 273
2013
Q2 		$375M Buy
+6,005,821
New +$381M 0.1% 253

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates's GSK Position: Q1 2026 in Review

T. Rowe Price Associates reduced its GSK (GSK) stake by 7.2% in Q1 2026, selling an estimated $31M and leaving 7,322,833 shares worth $404M. The position accounts for 0.05% of the portfolio, ranked #290.

T. Rowe Price Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $719M in Q2 2020. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • T. Rowe Price Associates held 7,322,833 shares of GSK worth $404M as of Q1 2026.
  • T. Rowe Price Associates sold 571,896 GSK shares in Q1 2026, an estimated $31M.
  • GSK made up 0.05% of T. Rowe Price Associates's portfolio in Q1 2026, its #290 holding.
  • T. Rowe Price Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's GSK position peaked at $719M in Q2 2020.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.